drugset / Trial / NCT03906721

Reduction of Opioid Dose Using Conditioning & Open-Label Placebo (COLP) in Patients With Spinal Cord Injury, Polytrauma and Burn Injury

NCT03906721

Phase 2 Completed 30 enrolled Spaulding Rehabilitation Hospital
RandomizedParallel-groupSingle-blindTreatment

Summary

The use of conditioning open-label placebo (COLP) will be studied as a dose extension method to lower opioid dosage in patients with spinal cord injury, polytrauma, and burn injury. The goal is to provide the same level of pain relief with a reduced opioid dose to diminish adverse effects as well as the risk of addiction associated with narcotic treatment.

Timeline

Start
2019-02-20
Primary completion
2021-11-01
Completion
2021-11-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxycodone Other / unclassified Oral

Indications